Compound TSYI-ZAC for inhibiting dengue virus infection and medicinal use thereof
AssigneeSyi Biotechnology Co., Ltd.
InventorsChia-Chang Chen, Guey-Chuen Perng, Hsiu-Man Lien, Yi-Ju Chen
Life of this patent
Estimating the term…
Abstract
A compound TSYI-ZAC (Zhankuic acid C) used in a method for treating dengue virus infection, in which a pharmaceutical composition can further comprise a 4,7-dimethoxy-5-methyl-1,3-benzodioxole compound capable of inhibiting dengue virus infection by down-regulating an expression of IL-6 and IL-8, and increasing a secretion of IFN-α.
Claims8
A method for treating dengue virus infection, comprising administrating an effective amount of a pharmaceutical composition comprising compound TSYI-ZAC and 4,7-dimethoxy-5-methyl-1,3-benzodioxole to a subject in need of, wherein the compound TSYI-ZAC is a Zhankuic acid C compound, a dose of the compound TSYI-ZAC is 5 μg/mL to 100 μg/mL, and a dose of 4,7-dimethoxy-5-methyl-1,3-benzodioxole compound is 5 μg/mL to 200 μg/mL.
A method for inhibiting dengue virus infection with a compound TSYI-ZAC, comprising contacting cells with the compound TSYI-ZAC to inhibit cells being infected by the dengue virus, wherein the compound TSYI-ZAC is a Zhankuic acid C compound, and a dose of the compound TSYI-ZAC is 5 μg/mL to 100 μg/mL.
Dependencies are inferred from the claim text.